Pazopanib
- PDF / 169,349 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 49 Downloads / 150 Views
1 S
Elevation of liver transaminases, nausea, vomiting and hypertension: 3 case reports In a retrospective cross-sectional file scanning study of 79 patients aged 19–86 years with advanced soft tissue sarcomas and who were treated between 01 January 2013 and 15 April 2019, 3 patients [ages and sexes not stated] were described, who developed elevation of liver transaminases, nausea, vomiting or hypertension during treatment with pazopanib [routes, durations of treatments to reactions onsets not stated; not all outcomes stated]. The patients, who had been diagnosed with advanced soft tissue sarcomas, started receiving pazopanib 800mg daily. However, during the treatment, the patients developed grade 3 elevation of liver transaminases (n=1), nausea and vomiting (n=1) and grade 3 resistant hypertension (n=1). The patient’s pazopanib dose was therefore reduced. At the end of the study, the pazopanib therapy was discontinued in two patients who developed elevation of liver transaminases and resistant hypertension, respectively. Karaagac M, et al. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort. Journal of 803520446 Oncology Pharmacy Practice 26: 1657-1666, No. 7, Oct 2020. Available from: URL: http://doi.org/10.1177/1078155220904138
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
